Abstract: Epidermal growth factor receptor tyrosine kinase inhibitor（EGFR-TKI） is the most widely used drug in the targeted treatment of lung cancer. However， almost all patients who are effective to this drug will eventually develop secondary resistance to EGFR-TKI. The main mechanism of resistance is that the EGFR associated signal pathway was again activated. The liver X receptor（LXR） belongs to the family of nuclear receptor. Many studies showed the inhibitory effects of LXR agonists on the signal pathway of PI3K/AKT/NF-κB that are important to EGFR. Therefore， LXR agonists may be a potential new choice that can reverse the secondary resistance of EGFR-TKI. This paper summarizes the recent findings about the inhibitory effects of LXR agonists on PI3K/AKT/NF-κB pathway.